FEDERAL Health Minister Greg Hunt last week announced an additional treatment option, Somatuline Autogel (lanreotide) from Ipsen will be listed on the Pharmaceutical Benefits Scheme for patients with a rare type of cancer, known as GEP-NETs or as gastroenteropancreatic neuroendocrine tumours.
It is expected that on average, 760 Australians will have subsidised access to this medicine each year, the department said.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Dec 18
